Optical Detection of Platelet Activation for Anti-Platelet Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-thrombotic therapies, such as clopidogrel, are ineffective in approximately 30% of patients due to genetic variations and polymorphisms in the P2Y12 receptor, leading to inadequate platelet inhibition and increased risk of cardiovascular events, with existing assays being costly and time-consuming, resulting in inappropriate treatment and significant economic waste.
Innovation Solution
A rapid and inexpensive diagnostic method using single particle optical light scattering and electrophoretic quasi-elastic light scattering techniques to determine if patients can respond to P2Y12 antagonists by measuring microparticle formation and platelet surface charge changes after exposure to agonists, allowing for personalized anti-thrombotic therapy selection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing assays are used to determine patient response to anti-thrombotic therapy, then measurement precision is improved, but loss of time and loss of money increase
Solution Approach 1:
The patent replaces complex mechanical/chemical assay systems with optical detection methods. Specifically, it uses light scattering techniques (dynamic light scattering, electrophoretic light scattering) to detect platelet activation states and microparticle formation, substituting time-consuming biochemical assays with rapid optical measurements that provide real-time data on patient response to anti-thrombotic therapy
Solution Approach 2:
The patent changes the measurement parameters from traditional biochemical markers to optical properties of platelets. By measuring light scattering intensity, particle size distribution, and electrophoretic mobility of platelets and microparticles, the system achieves rapid assessment of platelet activation status and drug response without requiring lengthy incubation or chemical processing steps
2Measurement precision
If existing assays are used to determine patient response to anti-thrombotic therapy, then measurement precision is improved, but loss of money increases
Solution Approach 1:
The patent replaces expensive biochemical reagents and complex assay procedures with optical detection technology. By using light scattering and electrophoretic mobility measurements, the system eliminates the need for costly enzymes, substrates, and specialized biochemical kits, providing an economical method for determining patient response to anti-thrombotic therapy
Solution Approach 2:
The patent employs a simplified, disposable-like approach by using direct optical measurement of patient samples without requiring expensive, reusable equipment calibration or complex reagent preparation. The method uses standard optical detectors and requires minimal sample processing, making each test economically viable and eliminating the need for expensive assay maintenance and reagent inventory
3Productivity
If rapid diagnostic methods are used, then productivity is improved, but measurement precision may worsen
Solution Approach 1:
The patent performs preliminary actions by directly measuring optical properties of platelets in their native state or after minimal processing. By measuring light scattering and electrophoretic mobility without requiring cell isolation, activation, or complex preparation steps, the system achieves both rapid diagnosis and accurate measurement of platelet activation status and drug response
Solution Approach 2:
The patent uses optical fields instead of mechanical manipulation to assess platelet properties. Light scattering patterns and electrophoretic mobility under electric fields provide immediate information about platelet size, shape, charge, and activation state, achieving both speed and precision by replacing time-consuming mechanical assays with instantaneous optical detection
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate identification of patients who will benefit from specific anti-thrombotic agents, reducing unnecessary treatment costs and improving treatment efficacy by tailoring therapy to individual patient responses, potentially preventing severe cardiovascular events.
Implementation Method 1
optical detection system to identify the presence or absence of microparticles
Implementation Method 2
electrophoretic quasi-elastic light scattering techniques to determine if patients can respond to P2Y12 antagonists by measuring microparticle formation and platelet surface charge changes
Data Source
AI summary
Diagnostic methods for determining whether an individual will benefit from a particular anti-thrombotic therapeutic agent are disclosed. The methods involve obtaining a biological sample that comprises platelets, from a patient who has been pre-administered a particular therapeutic agent, which is an antagonist of a receptor associated with the biochemical pathways involved in platelet aggregation, and exposing the platelets to an agonist of the receptor. If the antagonist is ineffective, the platelets will eject microparticles, will have a different size distribution than platelets not exposed to the agonist, and will experience a change in their surface charge. In one embodiment, the diagnostic methods involve using single particle optical sizing techniques to determine the presence of such ejected microparticles, or a change in platelet size due to its activation by the agonist. In another embodiment, electrophoretic quasi-elastic light scattering techniques are used to determine the presence of a change in surface charge on the platelets. Once an effective therapeutic agent, or an effective dosage of such therapeutic agent, has been identified, the patient can begin therapy knowing that the agent will be effective.